2026年6月最新影响因子数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
体验更多LetPub AI科研工具 >> | |
| 近期推荐： | 热 Wiley 2026暑期线上学习营 | 报名正式开启！ | 热 最高IF18.6！生命科学SCI明星期刊集锦 | 热 肿瘤免疫/自身免疫全覆盖｜免疫学SCI期刊列表 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | JOURNAL OF CLINICAL ONCOLOGY J CLIN ONCOL （此期刊被最新的JCR期刊SCIE收录） LetPub评分 9.9
53人评分
我要评分
声誉 9.9 影响力 9.9 速度 9.1 | |||||||||||||||||||||
| 期刊ISSN | 0732-183X | 安装APP，查看期刊最新消息
| ||||||||||||||||||||
| E-ISSN | 1527-7755 | |||||||||||||||||||||
| 2025-2026最新IF （数据来源于网友提供） | 注册或登录后，查看IF | |||||||||||||||||||||
| 实时影响因子 | 截止2026年5月06日：42.85 | |||||||||||||||||||||
| 2025-2026自引率 | 1.6%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年IF （数据来源于网友提供） | 41.302数据由网友[等待runner]收集提供 | |||||||||||||||||||||
| h-index | 494 | |||||||||||||||||||||
| CiteScore （ 2026年6月最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | http://jco.ascopubs.org/ | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/JCO-ASCOPUBS | |||||||||||||||||||||
| 该期刊中国学者近期发文 - New | Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial Author: Leonard, John P.; Trneny, Marek; Zhang, Huilai; Nowakowski, Grzegorz S.; Izutsu, Koji; Fowler, Nathan; Thieblemont, Catherine; Zinzani, Pier Luigi; Gkasiamis, Argyrios; Ahn, Jung Ryun; Gribben, John G Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 16, pp. 1483-1489. DOI: 10.1200/JCO-25-01770 Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002) Author: Chen, Baoqing; Liu, Shiliang; Zhu, Yujia; Zhang, Jingjing; Bao, Yong; Meng, Fanjun; Zhang, Li; Cheng, Xingyuan; Xuzhang, Wendi; Chen, Biqi; Wang, Ruixi; Li, Zimeng; Hu, Yonghong; Liu, Mengzhong; Lv, Yingxin; Li, Jibin; Dragomir, Mihnea P.; Chen, Ming; Li, Qiaoqiao; Yang, Hong; Xi, Mian Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 16, pp. 1508-1519. DOI: 10.1200/JCO-25-03044 Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability-High Gastric Cancer: Solid Evidence or Premature Extrapolation? Author: Zheng, Guoliang; Zhang, Xin; Zhang, Jing; Zheng, Zhendong; Zhao, Yan Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 15, pp. 1471-1472. DOI: 10.1200/JCO-25-02546 Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors Author: Vieito, Maria; Fontana, Elisa; Han, Catherine H.; Castanon, Eduardo; Pinato, David J.; Bechter, Oliver; Eefsen, Rikke L.; Moreno, Irene; Prenen, Hans; Dummer, Reinhard; Plummer, Ruth; Schnetzler, Gabriel; Kornacker, Martin; Pettazzoni, Piergiorgio; Renner, Florian; About, Mahdi; Serrano-Serrano, Martha L.; Godfried Sie, Christina; Keelara, Abiraj; Roller, Andreas; Dejardin, David; Cinato, Elisa; Fakolade, Tomi; Guarin, Ernesto; Flinn, Nick; Kratochwil, Nicole A.; Keshelava, Nino Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 14, pp. 1337-1348. DOI: 10.1200/JCO-25-02444 | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足JOURNAL OF CLINICAL ONCOLOGY的语言要求，还能让JOURNAL OF CLINICAL ONCOLOGY编辑和审稿人得到更好的审稿体验，让稿件最大限度地被JOURNAL OF CLINICAL ONCOLOGY编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | AMER SOC CLINICAL ONCOLOGY, 2318 MILL ROAD, STE 800, ALEXANDRIA, USA, VA, 22314 | |||||||||||||||||||||
| 出版商 | American Society of Clinical Oncology | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Biweekly | |||||||||||||||||||||
| 出版年份 | 1983 | |||||||||||||||||||||
| 年文章数 | 308点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 36.39% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 97.08% | |||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
  | ||||||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0732-183X%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均2月 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 约20% | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在JOURNAL OF CLINICAL ONCOLOGY顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial Author: Leonard, John P.; Trneny, Marek; Zhang, Huilai; Nowakowski, Grzegorz S.; Izutsu, Koji; Fowler, Nathan; Thieblemont, Catherine; Zinzani, Pier Luigi; Gkasiamis, Argyrios; Ahn, Jung Ryun; Gribben, John G Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 16, pp. 1483-1489. DOI: 10.1200/JCO-25-01770 PubMed DOI |
| 2. | Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002) Author: Chen, Baoqing; Liu, Shiliang; Zhu, Yujia; Zhang, Jingjing; Bao, Yong; Meng, Fanjun; Zhang, Li; Cheng, Xingyuan; Xuzhang, Wendi; Chen, Biqi; Wang, Ruixi; Li, Zimeng; Hu, Yonghong; Liu, Mengzhong; Lv, Yingxin; Li, Jibin; Dragomir, Mihnea P.; Chen, Ming; Li, Qiaoqiao; Yang, Hong; Xi, Mian Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 16, pp. 1508-1519. DOI: 10.1200/JCO-25-03044 PubMed DOI |
| 3. | Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability-High Gastric Cancer: Solid Evidence or Premature Extrapolation? Author: Zheng, Guoliang; Zhang, Xin; Zhang, Jing; Zheng, Zhendong; Zhao, Yan Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 15, pp. 1471-1472. DOI: 10.1200/JCO-25-02546 PubMed DOI |
| 4. | Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors Author: Vieito, Maria; Fontana, Elisa; Han, Catherine H.; Castanon, Eduardo; Pinato, David J.; Bechter, Oliver; Eefsen, Rikke L.; Moreno, Irene; Prenen, Hans; Dummer, Reinhard; Plummer, Ruth; Schnetzler, Gabriel; Kornacker, Martin; Pettazzoni, Piergiorgio; Renner, Florian; About, Mahdi; Serrano-Serrano, Martha L.; Godfried Sie, Christina; Keelara, Abiraj; Roller, Andreas; Dejardin, David; Cinato, Elisa; Fakolade, Tomi; Guarin, Ernesto; Flinn, Nick; Kratochwil, Nicole A.; Keshelava, Nino Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 14, pp. 1337-1348. DOI: 10.1200/JCO-25-02444 PubMed DOI |
| 5. | Systemic Treatment of Thyroid Cancer: ASCO Guideline Author: Saba, Nabil F.; Ismaila, Nofisat; Adkins, Douglas; Agrawal, Nishant; Akhave, Neil; Blomain, Erik S.; Cabanillas, Maria E.; Chen, Amy; Galloway, Thomas J.; Harada, Guilherme; Li, Dapeng; Noureldine, Salem I.; Scharpf, Joe; Sun, Lova L.; Tang, Mei; Wirth, Lori; Worden, Francis; Zandberg, Dan P.; Beadle, Beth M Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 14, pp. 1349-1372. DOI: 10.1200/JCO-26-00235 PubMed DOI |
| 6. | Methodologic Considerations for Subsequent Colorectal Cancer in Survivors of Childhood Cancer Author: Liu, Yixin; Liu, Yin; Wei, Yongchang Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 14, pp. 1375-1376. DOI: 10.1200/JCO-25-02569 PubMed DOI |
| 7. | Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery Author: Wang, Xuan; Li, Xudong; Jiang, Xiaobing Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 13, pp. 1266-1266. DOI: 10.1200/JCO-25-01988 PubMed DOI |
| 8. | Fullerene for Reducing Acute Radiation Dermatitis in Patients Undergoing Radiotherapy for Head and Neck Cancer: A Phase II, Double-Blind, Randomized Controlled Trial Author: Liu, Zheran; Liu, Xiaoxia; Li, Zhihui; Xie, Jiani; Gao, Kun; Pei, Yiyan; Gu, Zhanjun; Peng, Xingchen Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 13, pp. 1206-1215. DOI: 10.1200/JCO-25-02264 PubMed DOI |
| 9. | Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial Author: Liu, Tianshu; Luo, Suxia; Yuan, Xianglin; Liu, Dong; Zhou, Zhaofei; Wang, Xin; Deng, Yanhong; Chen, Jun; Liu, Mulin; Zhou, Huan; Ren, Xiubao; Qiu, Wensheng; Cao, Yu; Cai, Shirong; Dong, Yugang; Zhang, Yanqiao; Wang, Wei; Liang, Jun; Xu, Pingsheng; Liu, Heli; Zhao, Kaijing; Fan, Yang; Dou, Ning; Huang, Chuanpei; Li, Jin Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 13, pp. 1225-1237. DOI: 10.1200/JCO-25-00716 PubMed DOI |
| 10. | From Thresholds to Tumor Sidedness: Reframing Human Epidermal Growth Factor Receptor 2 in Colorectal Cancer Author: Liang, Xinjun; Lei, Hao Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 13, pp. 1268-1269. DOI: 10.1200/JCO-25-02335 PubMed DOI |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共117条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
